Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer
The efficacy of immunotherapy for HGECs remains limited, partly because current preclinical models poorly capture tumor heterogeneity and patient-specific immune microenvironment. These cancers disproportionately affect women of African ancestry, yet most studies rely on European ancestry samples. We developed an autologous PDO and immune cell coculture platform from patients of diverse ancestries. This system enables patient-level analysis of tumor-immune interactions to support development and testing of novel immunotherapeutic strategies.
Authors
- Semir Beyaz (ORCID: https://orcid.org/0000-0003-4730-4012)
- Arisa Kapedani
- Ariel Kredentser
- Charlie Chung (ORCID: https://orcid.org/0000-0003-1566-9498)
- Aaron Nizam (ORCID: https://orcid.org/0000-0002-6433-0370)
- Brian Yueh
- Werner Meier
- Alexander Krasnitz (ORCID: https://orcid.org/0000-0002-9465-0308)
- Onur Eskiocak
- Pascal Belleau
- Gary L. Goldberg
- Ken Simon
- Marina Frimer
Institutions
- Northwell Health (US)
- Feinstein Institute for Medical Research (US)
- Hofstra University (US)
- Cold Spring Harbor Laboratory (US)
- Concord Consortium (US)
- Stony Brook University (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2026-02-19
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0193
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00